Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Medite Cancer Diagnostics, Inc. | mdit8k_oct262016.htm |
| EX-10.1 - EXECUTIVE EMPLOYMENT AGREEMENT - Medite Cancer Diagnostics, Inc. | ex10-1.htm |
Exhibit 99.1
MEDITE
Cancer Diagnostics, Inc.
Announces Management Changes
Orlando, Fl., November 1, 2016 -MEDITE
Cancer Diagnostics, Inc., (OTCQB:MDIT, the “Company”)
specializing in the development, manufacturing, and marketing of
molecular biomarkers and premium medical devices for detection,
risk assessment and diagnosis of cancer and precancerous conditions
announces the following appointments effective
immediately:
-
David
Patterson as Chief Executive Officer
-
Michael
Ott as Chairman of MEDITE Cancer Diagnostics, Inc. and CEO of
MEDITE GmbH, Germany, the wholly owned subsidiary
-
Michaela Ott as
Chief Operating Officer
David
Patterson a former Executive Vice President specializing in
corporate development, marketing and strategy during his 30 year
career with Cigna, Phillips Health care and other companies will
become the Chief Executive Officer of MEDITE Cancer Diagnostics,
Inc. “MEDITE has worked with David in his role as an
independent consultant since November 2015. We believe
David’s past results and experience can assist MEDITE in
building the infrastructure for substantial growth of United States
sales which currently is approximately 5% of overall sales. We also
believe David’s international knowledge, experience and
contacts will be important factors involving the launch of our new
products,” says Michaela Ott now Chief Operating Officer and
former CEO of the Company. “As CEO of the Company’s
wholly owned subsidiary, I look forward in assisting David
implement the Company’s plans and strategy worldwide with the
assistance of our German operations,” says Michael Ott,
Chairman of MEDITE Cancer Diagnostics, Inc. and CEO of the German
subsidiary, MEDITE GmbH. “I am truly excited about the future
of the company as we look to substantially grow United States sales
and launch our new world class products worldwide as more efficient
and cost effective solutions in the detection of cancer and cancer
related diseases. I also look forward to working with the talented
and dedicated people of MEDITE”says David Patterson the new
CEO of MEDITE Cancer Diagnostics, Inc.
Effective
immediately, Michaela Ott, will resign as Chief Executive Officer,
Michael Ott will resign as Chief Operating Officer and Robert
McCullough, Jr. will resign as Chairman of the Board of MEDITE
Cancer Diagnostics, Inc. McCullough will remain as Chief Financial
Officer. All three will remain on the Board of Directors with
respect to their positions
About MEDITE Cancer Diagnostics, Inc.
MEDITE
Cancer Diagnostics Inc., is a Delaware registered company
consisting of wholly-own MEDITE GmbH a Germany-based company with
its subsidiaries. On April 3, 2014, MEDITE was acquired by former
CytoCore, Inc. a biomolecular diagnostics company engaged in the
design, development, and commercialization of cost-effective cancer
screening systems and Biomarkers to assist in the early detection
of cancer. By acquiring MEDITE the company changed from solely
research operations to an operating company with a well-developed
infrastructure, 78 employees in four countries, a distribution
network to about 70 countries worldwide, a well-known and
established brand name and a wide range of products for anatomic
pathology, histology and cytology laboratories.
Forward Looking Statement
This press release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
regarding future operating performance, events, trends and plans.
All statements other than statements of historical fact contained
herein, including, without limitation, statements regarding our
future financial position, business strategy, budgets, projected
revenues and costs, and plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as “may,”
“will,” “expects,” “intends,”
“plans,” “projects,”
“estimates,” “anticipates,” or
“believes” or the negative thereof or any variation
thereon or similar terminology or expressions. We have based these
forward-looking statements on our current expectations and
projections about future events. These forward-looking statements
are not guarantees and are subject to known and unknown risks,
uncertainties and assumptions about us that may cause our actual
results, levels of activity, performance or achievements to be
materially different from any future results, levels of activity,
performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause our
actual results to differ from our expectations, include but are not
limited to, MEDITE’s ability to maintain and grow its
revenues. Readers are cautioned not to place undue reliance on our
forward-looking statements, as they speak only as of the date made.
Such statements are not guarantees of future performance or events
and we undertake no obligation to disclose any revision to these
forward-looking statements to reflect events or circumstances
occurring after the date hereof.
For more information please visit: www.medite-group.com
Investor Contact:
David Patterson CEO
317-341-3589